KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial.

Philip J Mease, Vinod Chandran, April W Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L Siegel, Alice B Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze-Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar

Arthritis Rheumatol 10.1002/art.70280

PMID42473780
PMCID-
DOI10.1002/art.70280
发表日期2026-07-20
入排依据:Study is a Phase 3 randomized trial of a drug intervention with original results, but it is not an oncology study of a human malignant neoplasm and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS).
摘要

摘要

OBJECTIVE: To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease-modifying antirheumatic drugs or received tumor necrosis factor inhibitors. METHODS: In the 52-week (W), double-blind, placebo-controlled, phase 3 POETYK PsA-2 study (NCT04908189), patients were randomized 3:3:1 to deucravacitinib 6 mg daily, placebo, or apremilast 30 mg twice daily (safety reference arm) through W16. From W16 to W52, patients continued receiving deucravacitinib or apremilast or switched from placebo to deucravacitinib. The primary endpoint was American College of Rheumatology 20% improvement in response (ACR20) at W16. Secondary endpoints were analyzed per prespecified order to control for multiplicity. RESULTS: Overall, 729 patients were randomized (312 deucravacitinib, 312 placebo, 105 apremilast). Significantly more patients achieved ACR20 at W16 with deucravacitinib versus placebo (54.2% vs 39.4%; P=0.0002); responses improved beyond W16 and were maintained through W52 (deucravacitinib-deucravacitinib, 62.2%; placebo-deucravacitinib, 67.3%). At W16, significant differences with deucravacitinib versus placebo were observed in hierarchal secondary endpoints of HAQ-DI, PASI-75, SF-36 PCS, and achievement of MDA. At W16, serious adverse events occurred in 1.0%, 1.9%, and 3.8% of patients with placebo, deucravacitinib, and apremilast, respectively. No new safety signals, deaths, or imbalances in cardiovascular events, malignancies, or opportunistic infections occurred through W52. CONCLUSION: Deucravacitinib was well-tolerated in patients with PsA and demonstrated superior efficacy versus placebo across multiple clinical endpoints and patient-reported outcomes, including functional ability and quality of life. Clinical responses and patient-reported outcomes were maintained through week 52.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。